Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
674.84B
Market cap674.84B
Price-Earnings ratio
42.59
Price-Earnings ratio42.59
Dividend yield
1.88%
Dividend yield1.88%
Average volume
7.86M
Average volume7.86M
High today
$281.25
High today$281.25
Low today
$276.61
Low today$276.61
Open price
$277.96
Open price$277.96
Volume
5.43M
Volume5.43M
52 Week high
$283.25
52 Week high$283.25
52 Week low
$189.05
52 Week low$189.05

Stock Snapshot

With a market cap of 674.84B, Johnson & Johnson(JNJ) trades at $280.55. The stock has a price-to-earnings ratio of 42.59 and currently yields dividends of 1.88%.

On 2026-11-11, Johnson & Johnson(JNJ) stock traded between a low of $276.61 and a high of $281.25. Shares are currently priced at $280.55, which is +1.4% above the low and -0.2% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 5.43M, against a daily average of 7.86M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $283.25 and a 52-week low of $189.05.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $283.25 and a 52-week low of $189.05.

JNJ News

The Motley Fool 3h
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?

Johnson & Johnson (JNJ -0.28%) has made significant business changes over the past few years. Perhaps the most notable was the company's decision to spin off it...

Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?
New York Times 3h
Giants are favored to win NFC East, but betting market ‘not sold’ on J.J. McCarthy - The New York Times

...

Giants are favored to win NFC East, but betting market ‘not sold’ on J.J. McCarthy - The New York Times
Simply Wall St 4h
Does Johnson & Johnson Have A New Growth Driver In Bipolar Mania?

Johnson & Johnson (NYSE:JNJ) reported positive topline results from a second pivotal Phase 3 trial of CAPLYTA for bipolar I mania. The study in adults with bip...

Does Johnson & Johnson Have A New Growth Driver In Bipolar Mania?

Analyst ratings

67%

of 27 ratings
Buy
66.7%
Hold
25.9%
Sell
7.4%

More JNJ News

Benzinga 5h
Johnson & Johnson Reports Favorable Data For Bipolar Study

Johnson & Johnson (NYSE:JNJ) reported topline results on Tuesday from Study 452, its second pivotal Phase 3 trial evaluating CAPLYTA (lumateperone) in adults wi...

Johnson & Johnson Reports Favorable Data For Bipolar Study
24/7 Wall St. 8h
SGOV Yields 3.63%. Can Johnson & Johnson or Verizon Pay Retirees More?

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

SGOV Yields 3.63%. Can Johnson & Johnson or Verizon Pay Retirees More?
24/7 Wall St. 1d
$300,000 in Duke Energy, Philip Morris and Johnson & Johnson: Here's What It Pays

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

$300,000 in Duke Energy, Philip Morris and Johnson & Johnson: Here's What It Pays
Simply Wall St 1d
Johnson & Johnson Shares Just Moved, So What Is Driving Attention Now?

Johnson & Johnson (JNJ) is back in focus after early Phase 1 data on its pasritamig and JNJ-9401 antibody combo in advanced prostate cancer, raising fresh quest...

Johnson & Johnson Shares Just Moved, So What Is Driving Attention Now?
Seeking Alpha 1d
J&J succeeds in second late-stage trial for Caplyta in bipolar mania

Johnson & Johnson (JNJ) on Tuesday announced that a second late-stage pivotal trial for its atypical antipsychotic Caplyta met its primary and key secondary end...

J&J succeeds in second late-stage trial for Caplyta in bipolar mania
TipRanks 2d
Johnson & Johnson Shareholder Investigation: Strong Earnings Can’t Mask MedTech’s Troubling Diagnosis

Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson (Johnson & Johnson) (NYSE:JNJ) concerning possible violations of...

Benzinga 2d
Johnson & Johnson Showcases Positive Trial Data For Key Autoimmune Therapies

Johnson & Johnson (NYSE:JNJ) highlighted encouraging clinical advancements on Saturday across two major immunology programs, presenting positive Phase 3 data fo...

Johnson & Johnson Showcases Positive Trial Data For Key Autoimmune Therapies

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.